A recommended scale for cognitive screening in clinical trials of Parkinson's disease.
Identifieur interne : 001545 ( PubMed/Corpus ); précédent : 001544; suivant : 001546A recommended scale for cognitive screening in clinical trials of Parkinson's disease.
Auteurs : Kelvin L. Chou ; Melissa M. Amick ; Jason Brandt ; Richard Camicioli ; Karen Frei ; Darren Gitelman ; Jennifer Goldman ; John Growdon ; Howard I. Hurtig ; Bonnie Levin ; Irene Litvan ; Laura Marsh ; Tanya Simuni ; Alexander I. Tröster ; Ergun Y. UcSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- MESH :
- complications : Cognition Disorders, Parkinson Disease.
- diagnosis : Cognition Disorders.
- psychology : Cognition Disorders, Parkinson Disease.
- Clinical Trials as Topic, Cognition, Humans, Neuropsychological Tests, Psychometrics, Questionnaires.
Abstract
Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD.
DOI: 10.1002/mds.23362
PubMed: 20878991
Links to Exploration step
pubmed:20878991Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A recommended scale for cognitive screening in clinical trials of Parkinson's disease.</title><author><name sortKey="Chou, Kelvin L" sort="Chou, Kelvin L" uniqKey="Chou K" first="Kelvin L" last="Chou">Kelvin L. Chou</name><affiliation><nlm:affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109-5316, USA. klchou@med.umich.edu</nlm:affiliation></affiliation></author><author><name sortKey="Amick, Melissa M" sort="Amick, Melissa M" uniqKey="Amick M" first="Melissa M" last="Amick">Melissa M. Amick</name></author><author><name sortKey="Brandt, Jason" sort="Brandt, Jason" uniqKey="Brandt J" first="Jason" last="Brandt">Jason Brandt</name></author><author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name></author><author><name sortKey="Frei, Karen" sort="Frei, Karen" uniqKey="Frei K" first="Karen" last="Frei">Karen Frei</name></author><author><name sortKey="Gitelman, Darren" sort="Gitelman, Darren" uniqKey="Gitelman D" first="Darren" last="Gitelman">Darren Gitelman</name></author><author><name sortKey="Goldman, Jennifer" sort="Goldman, Jennifer" uniqKey="Goldman J" first="Jennifer" last="Goldman">Jennifer Goldman</name></author><author><name sortKey="Growdon, John" sort="Growdon, John" uniqKey="Growdon J" first="John" last="Growdon">John Growdon</name></author><author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I" last="Hurtig">Howard I. Hurtig</name></author><author><name sortKey="Levin, Bonnie" sort="Levin, Bonnie" uniqKey="Levin B" first="Bonnie" last="Levin">Bonnie Levin</name></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name></author><author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name></author><author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I" last="Tröster">Alexander I. Tröster</name></author><author><name sortKey="Uc, Ergun Y" sort="Uc, Ergun Y" uniqKey="Uc E" first="Ergun Y" last="Uc">Ergun Y. Uc</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.23362</idno><idno type="RBID">pubmed:20878991</idno><idno type="pmid">20878991</idno><idno type="wicri:Area/PubMed/Corpus">001545</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A recommended scale for cognitive screening in clinical trials of Parkinson's disease.</title><author><name sortKey="Chou, Kelvin L" sort="Chou, Kelvin L" uniqKey="Chou K" first="Kelvin L" last="Chou">Kelvin L. Chou</name><affiliation><nlm:affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109-5316, USA. klchou@med.umich.edu</nlm:affiliation></affiliation></author><author><name sortKey="Amick, Melissa M" sort="Amick, Melissa M" uniqKey="Amick M" first="Melissa M" last="Amick">Melissa M. Amick</name></author><author><name sortKey="Brandt, Jason" sort="Brandt, Jason" uniqKey="Brandt J" first="Jason" last="Brandt">Jason Brandt</name></author><author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name></author><author><name sortKey="Frei, Karen" sort="Frei, Karen" uniqKey="Frei K" first="Karen" last="Frei">Karen Frei</name></author><author><name sortKey="Gitelman, Darren" sort="Gitelman, Darren" uniqKey="Gitelman D" first="Darren" last="Gitelman">Darren Gitelman</name></author><author><name sortKey="Goldman, Jennifer" sort="Goldman, Jennifer" uniqKey="Goldman J" first="Jennifer" last="Goldman">Jennifer Goldman</name></author><author><name sortKey="Growdon, John" sort="Growdon, John" uniqKey="Growdon J" first="John" last="Growdon">John Growdon</name></author><author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I" last="Hurtig">Howard I. Hurtig</name></author><author><name sortKey="Levin, Bonnie" sort="Levin, Bonnie" uniqKey="Levin B" first="Bonnie" last="Levin">Bonnie Levin</name></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name></author><author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name></author><author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I" last="Tröster">Alexander I. Tröster</name></author><author><name sortKey="Uc, Ergun Y" sort="Uc, Ergun Y" uniqKey="Uc E" first="Ergun Y" last="Uc">Ergun Y. Uc</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical Trials as Topic</term><term>Cognition</term><term>Cognition Disorders (complications)</term><term>Cognition Disorders (diagnosis)</term><term>Cognition Disorders (psychology)</term><term>Humans</term><term>Neuropsychological Tests</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (psychology)</term><term>Psychometrics</term><term>Questionnaires</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cognition Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Cognition Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Cognition</term><term>Humans</term><term>Neuropsychological Tests</term><term>Psychometrics</term><term>Questionnaires</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20878991</PMID><DateCreated><Year>2010</Year><Month>11</Month><Day>11</Day></DateCreated><DateCompleted><Year>2011</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>15</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>A recommended scale for cognitive screening in clinical trials of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>2501-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23362</ELocationID><Abstract><AbstractText>Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD.</AbstractText><CopyrightInformation>© 2010 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Kelvin L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan 48109-5316, USA. klchou@med.umich.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amick</LastName><ForeName>Melissa M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Brandt</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Camicioli</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Frei</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gitelman</LastName><ForeName>Darren</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hurtig</LastName><ForeName>Howard I</ForeName><Initials>HI</Initials></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Simuni</LastName><ForeName>Tanya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tröster</LastName><ForeName>Alexander I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Uc</LastName><ForeName>Ergun Y</ForeName><Initials>EY</Initials></Author><Author ValidYN="Y"><CollectiveName>Parkinson Study Group Cognitive/Psychiatric Working Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>#MH069666</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD39822 M032413</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS060949</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS060949-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23060949</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS037167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS36630-08</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS44504-08</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50NS38377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS36711-05A2</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 NS044504-09</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S140-2</RefSource><PMID Version="1">10609693</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Mar 15;25(4):440-6</RefSource><PMID Version="1">20155863</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Nov 11;61(9):1222-8</RefSource><PMID Version="1">14610124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Psychiatr Res. 1975 Nov;12(3):189-98</RefSource><PMID Version="1">1202204</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 1992 Sep;40(9):922-35</RefSource><PMID Version="1">1512391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 1993 May 12;269(18):2386-91</RefSource><PMID Version="1">8479064</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1994 Mar;151(3):390-6</RefSource><PMID Version="1">8109647</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Geriatr Psychiatry. 1997 Jan;12(1):101-8</RefSource><PMID Version="1">9050431</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Age Ageing. 1999 Jan;28(1):39-43</RefSource><PMID Version="1">10203203</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2004 Dec;61(12):1906-11</RefSource><PMID Version="1">15596611</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 2005 Apr;53(4):695-9</RefSource><PMID Version="1">15817019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Age Ageing. 2005 May;34(3):268-73</RefSource><PMID Version="1">15863411</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Suppl. 2006;(71):27-30</RefSource><PMID Version="1">17447412</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837</RefSource><PMID Version="1">17542011</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2007 Nov;78(11):1182-7</RefSource><PMID Version="1">17442759</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Dec;22(16):2314-24</RefSource><PMID Version="1">18098298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Jan;23(1):81-7</RefSource><PMID Version="1">17987646</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Jan 30;23(2):297-9</RefSource><PMID Version="1">18044697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2008;14(2):93-101</RefSource><PMID Version="1">17707678</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2008 Feb;255(2):255-64</RefSource><PMID Version="1">18204803</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Apr 30;23(6):837-44</RefSource><PMID Version="1">18307261</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 May 15;23(7):1043-6</RefSource><PMID Version="1">18381646</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 May 15;23(7):998-1005</RefSource><PMID Version="1">18381647</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Aug 15;23(11):1546-50</RefSource><PMID Version="1">18546326</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurol. 2009 Jan;16(1):142-7</RefSource><PMID Version="1">19049504</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 2009 Feb;57(2):304-8</RefSource><PMID Version="1">19170786</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Jun 15;24(8):1103-10</RefSource><PMID Version="1">19353727</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Nov 3;73(18):1469-77</RefSource><PMID Version="1">19884574</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Nov 24;73(21):1738-45</RefSource><PMID Version="1">19933974</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):708-12</RefSource><PMID Version="1">12023410</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003071">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009483">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011594">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS219584</OtherID><OtherID Source="NLM">PMC2978783</OtherID><InvestigatorList><Investigator ValidYN="Y"><LastName>Uc</LastName><ForeName>Ergun</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chou</LastName><ForeName>Kelvin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adler</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Punit</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amick</LastName><ForeName>Melissa M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandt</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camicioli</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frei</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerstenhaber</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gitelman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardesty</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartlein</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hermanowicz</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hui</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hurtig</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsh</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nirenberg</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panisset</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richard</LastName><ForeName>Irene H</ForeName><Initials>IH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>Web</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simuni</LastName><ForeName>Tanya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tröster</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Truong</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuite</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2010</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23362</ArticleId><ArticleId IdType="pubmed">20878991</ArticleId><ArticleId IdType="pmc">PMC2978783</ArticleId><ArticleId IdType="mid">NIHMS219584</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001545 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001545 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:20878991
|texte= A recommended scale for cognitive screening in clinical trials of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20878991" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |